Onconetix, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-07.
Onconetix, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 7, 2025. The filing reports $12.98M sold. Its industry group is Biotechnology. It names Karina Fedasz (Executive Officer), Simon Tarsh (Director), Timothy Ramdeen (Director) (SEC Form D, October 7, 2025).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Onconetix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-07 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Onconetix, Inc.
Free to see. No signup.
More on the people and the money behind Onconetix, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Onconetix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Onconetix, Inc. raises, hires or launches. No email unless you switch it on.
Watch Onconetix, Inc. →Get the full cited report on Onconetix, Inc.
What the filing shows about Onconetix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Onconetix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Onconetix, Inc.'s address as 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Onconetix, Inc. is a registered filer with the SEC (CIK 1782107) and has filed since 2024-10-17. 2 filings are on record, the latest on 2025-10-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Onconetix, Inc.'s Form D of 2025-10-07 names Karina Fedasz, Simon Tarsh, Timothy Ramdeen and 2 more as its officers, directors or promoters.
Its new offerings report $14.98M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Karina Fedasz is named as Executive Officer on the Form D that Onconetix, Inc. filed with the SEC on 7 October 2025, one of 5 people that filing names.
Simon Tarsh is named as Director on the Form D that Onconetix, Inc. filed with the SEC on 7 October 2025, one of 5 people that filing names.
Timothy Ramdeen is named as Director on the Form D that Onconetix, Inc. filed with the SEC on 7 October 2025, one of 5 people that filing names.
Thomas Meier is named as Director on the Form D that Onconetix, Inc. filed with the SEC on 7 October 2025, one of 5 people that filing names.
Andrew Oakley is named as Director on the Form D that Onconetix, Inc. filed with the SEC on 7 October 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-10-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Onconetix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Onconetix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Onconetix, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Onconetix, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Onconetix, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Onconetix, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/onconetix-inc-form-d-25000001